Back to RecallTracker
Health Canada Health products

Skin-cancer drug Zelboraf (vemurafenib): new warning on the risk of pancreatitis

Issued February 12, 2015
Issue
Hazard description
New safety information - Product safety
What to do
Patients taking Zelboraf who experience severe pain in the upper abdomen (belly), accompanied by nausea, vomiting, or abdominal tenderness, should stop taking Zelboraf and talk to their health professional right away. Pancreatitis is a potentially serious condition requiring medical attention.